Clinical Trial Update: A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment [Phase 1]

View source ↗

Summary

Phase 1 trial update assessing Evacetrapib in participants with hepatic impairment has completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Insufficiency
• Liver Disease

Drugs mentioned

• Evacetrapib

Snippet

Sponsor: Eli Lilly and Company | Conditions: Hepatic Insufficiency | Phase 1 | Status: COMPLETED | Results posted: 2018-10-12